Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3914-3916

  Pankuch, Glenn A ^a   Hoellman, Dianne ^a   Bryskier, André ^b   Lowther, John ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Novexel SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; DALFOPRISTIN PLUS QUINUPRISTIN; KETOLIDE; MACROLIDE; NXL 103; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RPR 132552A; RPR 202868; STREPTOGRAMIN; UNCLASSIFIED DRUG; XRP 2868;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; COMPARATIVE STUDY; CULTURE MEDIUM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS TEST MEDIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STORAGE TEMPERATURE;

ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HAEMOPHILUS INFLUENZAE; MICROBIAL SENSITIVITY TESTS; STREPTOGRAMIN A; STREPTOGRAMIN B; STREPTOGRAMINS;

EID: 33750594525     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00587-06     Document Type: Article

References (12)

1. Dagan, R., C. E. Johnson, S. McLinn, N. Abughali, J. Feris, E. Leibovitz, D. J. Burch, and M. R. Jacobs. 2000. Bacteriological and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr. Infect. Dis. J. 19:95-104.
2. Dagan, R., E. Leibovitz, D. M. Fliss, A. Lieberman, M. R. Jacobs, W. Craig, and P. Yagupsky. 2000. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob. Agents Chemother. 44:43-50.
3. Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic. 2005. Susceptibility of European β-lactamase-positive and -negative Haemophilia influenzae isolates from the periods 1997/1998 and 2002/2003. J. Antimicrob. Chemother. 56:133-138.
4. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, H. T. Fernandez, and A. Bryskier. 2005. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob. Agents Chemother. 49:408-413.
5. Jacobs, M. R. 2001. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7:589-596.
6. Mabe, S., and W. S. Champney. 2005. A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. Curr. Microbiol. 51:361-363.
7. Matic, V., B. Bozdogan, M. R. Jacobs, K. Ubukata, and P. C. Appdbaum. 2003. Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J. Antimicrob. Chemother. 52:1018-1021.
8. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards. Wayne, Pa.
9. Pankuch, G. A., L. M. Kelly, G. Lin, A. Bryskier, C. Couturier, M. R. Jacobs, and P. C. Appelbaum. 2003. Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species. Antimicrob. Agents Chemother. 47:3270-3274.
10. Peric, M., B. Bozdogan, C. Galderisi, D. Krissinger, T. Rager, and P. C. Appelbaum. 2004. Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S. J. Antimicrob. Chemother. 54:393-400.
11. Peric, M., B. Bozdogan, M. R. Jacobs, and P. C. Appelbaum. 2003. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 47:1017-1022.
12. Zeckel, M. L., K. D. Jacobson, F. J. Guerra, D. G. Therasse, and D. Farlow. 1992. Loracarbef (LY 163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Ther. 14:214-229.